Roche launches Elecsys Anti-p53 immunoassay to help in cancer diagnosis

Swiss healthcare company Roche has launched the Elecsys Anti-p53 immunoassay to help in the diagnosis of various types of cancer by the in vitro quantitative determination of anti-p53 antibodies.

The Anti-p53 immunoassay test will help physicians in diagnosing oesophageal cancer, breast cancer, and bowel cancer in patients, in combination with other diagnostic tests, said Roche.

The Swiss healthcare company said that the new assay is available for all markets that accept the CE Mark.

Roche launches Elecsys Anti-p53 immunoassay to help in cancer diagnosis. Photo courtesy of F. Hoffmann-La Roche Ltd.

Thomas Schinecker – CEO of Roche Diagnostics said: “The addition of our Elecsys Anti-p53 immunoassay will help clinicians to quickly and reliably diagnose several prevalent cancers and might assist in leading to a better prognosis for many patients.

“Beyond breakthrough cancer medicines, Roche also offers a growing number of testing solutions to help physicians diagnose and treat people with cancer.”

According to Roche, Elecsys Anti-p53 is a high precision immunoassay, which delivers a low turn-around time for testing, and complements its overall tumor marker portfolio.

It uses the electrochemiluminescence immunoassay (ECLIA) technology and is intended to be used on Roche’s cobas e immunoassay analyzers.